The "Yes" link below will take you out of the Abbott Laboratories family of websites.
Links which take you out of Abbott Laboratories worldwide web sites are not under the
control of Abbott Laboratories, and Abbott Laboratories is not responsible for the
contents of any such site or any further links from such site. Abbott Laboratories is
providing these links to you only as a convenience, and the inclusion of any link does
not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?
 

Coronary Bioresorbable Vascular Scaffolds

 

Introduction

Absorb: The World’s First Fully Bioresorbable Vascular Scaffold

Absorb

Absorb: Clinical Evidence Along the Continuum

Absorb Clinical Evidence Along the Continuum

 

1. Yamaji, K., et al. Very Long-Term Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation, Circ Cardiovasc Interv. 2010: DOI; 10.1161/CIRCINTERVENTIONS.110.958249
2. Serruys, P.W.,et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis, 5-Year Follow-Up, J Am Coll Cardiol. 2016; DOI: 10.1016/j.jacc.2015.11.060
3. Hernandez, F., REPARA, ESC2015;
4. Hamm, C., GABI-R, EuroPCR2015;
5. Serruys, P.W., et al. TROFI II, Eur Heart J.2015; DOI: 10.1093/eurheartj/ehv500;
6. DeLaTorre Hernandez, J., ESTROFA-BVS, EuroPCR2015;
7. Ellis, S., et al. ABSORB III 1-Year, New Engl J Med. 2015; DOI:1056/NEJMoa1509038;
8. Kimura, T., et al. ABSORB Japan, Eur Heart J. 2015; DOI:10.1093/eurheartj/ehv435;
9. Gao, R., et al. ABSORB China, J Am Coll Cardiol. 2015; DOI:1016/j.jacc.2015.09.054.;
10. Seth,A., ABSORB-FIRST, TCT2015;
11. Capranzano, P., GHOST-EU, EuroPCR2015;
12. Chevalier, B., ABSORB II, TCT2015;
13. Schwenke, ASSURE, TCT2015;
14. Bartorelli, A., ABSORB Extend, TCT 2015;
15. Serruys, P.W.,et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis, 5-Year Follow-Up, J Am Coll Cardiol. 2016; DOI: 10.1016/j.jacc.2015.11.060

 

Product Overview

Absorb and Absorb GT1: Bioresorbable Vascular Scaffold (BVS) Systems

Absorb

Absorb and Absorb GT1 BVS systems repair stenosed vessels and elutes everolimus similarly to XIENCE family of products+ but also resorbs naturally into the body leaving no permanent implant*.

 

 

 

Science of Absorb

 

 

Absorb GT1 Design Elements

Absorb GT1 Design Elements

 

Repair Restore Renew*Small platinum markers at scaffold edge remain for fluoroscopic landmarking.
†Improved as compared to Absorb BVS. Tests performed by and data on file at Abbott Vascular.
+XIENCE family of products: XIENCE V, XIENCE Prime, XIENCE Xpedition, XIENCE Alpine

 

Efficacy

Absorb: Proven Efficacy Comparable to Best-in Class DES1,2

Absorb Efficacy

Restored Vascular Function, Late Lumen Gain and Reduction in Plaque Area for Sustained Low Event Rates

Absorb Efficacy

 

Repair Restore RenewABSORB Meta rates are binary rates; GHOST EU rates are based on Kaplan-Meier estimates *Digitized from curves in Serruys, PW, ABSORB Cohort B, TCT 2015
1. Stone, GW., et al.1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis, Lancet 2016; DOI: 10.2016/S0140-6736(15)01039-9;
2. Capodanno, D., et al. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everoliumus-Eluting Stents, A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries., JACC : Cardiovascular Interventions 2016; DOI: 10.1016/j.jcin.2015.10.042;
3. Serruys, P.W.,et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis, 5-Year Follow-Up, J Am Coll Cardiol. 2016; DOI: 10.1016/j.jacc.2015.11.060

Safety

Absorb: Proven Safety Comparable to Best-In-Class DES

Absorb Safety

 

Repair Restore Renew*Subset Analysis in vessels ≥2.25mm by QCA, representing more than 80% of patients enrolled in the ABSORB III trial. ABSORB III thrombosis results in vessels <2.25 mm, representing 18% of the patients, were 4.6% Absorb vs. 1.5% for XIENCE.
1. Stone, GW., et al.1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis, Lancet 2016; DOI: 10.2016/S0140-6736(15)01039-9
2. Capodanno, D., et al. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everoliumus-Eluting Stents, A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries, JACC : Cardiovascular Interventions 2016; DOI: 10.1016/j.jcin.2015.10.042;
3. Kereiakes, D., ABSORB III, TCT 2015

 

Ordering Information

Ordering Information

Absorb Product Numbers

 

Repair Restore Renew

 

Optimal Implantation

Absorb and Absorb GT1: THE 5 Ps FOR OPTIMAL IMPLANTATION TECHNIQUE

Optimal Implantation Technique

Repair Restore Renew

 

AP2937989-WBO Rev. B